Programmed cell death

NF-Kappa B Inhibitors Clinical Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021

The "NF-Kappa B Inhibitors - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "NF-Kappa B Inhibitors - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "NF-kappa B Inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in NF-kappa B Inhibitors pipeline landscape.
  • This segment of the NF-kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • NF-kappa B Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Apoptosis Regulator BAX Drugs Development Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021

The "Apoptosis Regulator BAX - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Apoptosis Regulator BAX - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene.
  • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 8 molecules.
  • The latest report Apoptosis Regulator BAX - Drugs In Development, 2021, outlays comprehensive information on the Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene

Retrieved on: 
Wednesday, June 30, 2021

The ULK kinase initiates the autophagy pathway and provides a potential targeted approach to selectively inhibiting autophagy in cancers caused by RAS or RAF mutations.

Key Points: 
  • The ULK kinase initiates the autophagy pathway and provides a potential targeted approach to selectively inhibiting autophagy in cancers caused by RAS or RAF mutations.
  • In preclinical studies, DCC-3116 was observed to potently and durably inhibit autophagy in RAS and RAF mutant cancer cell lines through the inhibition of ULK kinase.
  • The Phase 1, multicenter, open-label, first-in-human study will evaluate DCC-3116 as a single agent and in combination with trametinib, an FDA-approved MEK inhibitor, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU

Retrieved on: 
Monday, June 21, 2021

In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.

Key Points: 
  • In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.
  • Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K- and PI3K- isoforms expressed in malignant B cells.
  • Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.
  • The clinical development program for Aliqopa also includes the Phase III study CHRONOS-4, evaluating Aliqopa in combination with standard immunochemotherapy in relapsed iNHL.

Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials

Retrieved on: 
Thursday, June 17, 2021

Anji Pharma (Anji), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the programs MCL1 inhibitors through clinical development.

Key Points: 
  • Anji Pharma (Anji), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the programs MCL1 inhibitors through clinical development.
  • MCL1 is a member of the Bcl-2 family, normally acting as a brake on the apoptosis pathway.
  • In many human cancers, the Mcl-1 gene is highly amplified, shifting the balance from pro- to anti-apoptotic signals and promoting cancer cell survival and tumor formation.
  • The MCL1 program is one of several programs pursued by the Center for Development of Therapeutics (CDoT) at the Broad Institute.

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

Retrieved on: 
Wednesday, June 9, 2021

This new patent completes, in a key territory, the already robust patent family protecting AsiDNA in combination with PARP inhibitors.

Key Points: 
  • This new patent completes, in a key territory, the already robust patent family protecting AsiDNA in combination with PARP inhibitors.
  • The DNA repair pathways, BRCA-dependent homologous recombination pathway and PARP pathway, are complementary and essential for tumor cell survival and proliferation.
  • If one pathway is deficient (homologous recombination by BRCA mutation) and the other is blocked by a PARP inhibitor, the tumor cell dies.
  • "This patent represents a further recognition in the strategic US market of the very original properties of AsiDNA.

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

Retrieved on: 
Wednesday, June 9, 2021

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Key Points: 
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • p53 mutations are found in approximately half of all cancers.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Kojin Therapeutics Launches with $60 Million Series A to Develop New Category of Drugs Based on Cell State Biology

Retrieved on: 
Wednesday, June 9, 2021

For many hard-to-treat diseases, including otherwise drug-resistant cancers, diseased cells are in a state that is sensitive to ferroptosis, or iron-dependent cell death.

Key Points: 
  • For many hard-to-treat diseases, including otherwise drug-resistant cancers, diseased cells are in a state that is sensitive to ferroptosis, or iron-dependent cell death.
  • At Kojin, we have pioneered a fundamentally new way of looking at biology that unlocks enormous potential for drug discovery, said Stuart Schreiber, co-founder of Kojin Therapeutics.
  • Understanding cell states allows us to determine how a cell behaves and to target cells previously thought untouchable in cancer and other diseases.
  • To learn more about how Kojin is drugging the ferroptosis-sensitive cell state, visit kojintx.com or follow us on LinkedIn or Twitter @KojinTx.

Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL

Retrieved on: 
Tuesday, June 8, 2021

Patients with CLL or intermediate-high TLS risk were initiated on a daily ramp-up schedule until the dose assigned before the study cycles.

Key Points: 
  • Patients with CLL or intermediate-high TLS risk were initiated on a daily ramp-up schedule until the dose assigned before the study cycles.
  • These patients received a median of 6 cycles (range: 1-24) of treatment with lisaftoclax.
  • Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
  • Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Retrieved on: 
Friday, June 4, 2021

VIP152, a potent and selective inhibitor of CDK9, has completed dose escalation in patients with advanced malignancies (NCT02635672).

Key Points: 
  • VIP152, a potent and selective inhibitor of CDK9, has completed dose escalation in patients with advanced malignancies (NCT02635672).
  • DHL is defined as a dual arrangement or overexpression of the MYC gene and either the B-cell lymphoma 2 (BCL2) or BCL6 genes.
  • Four patients had 2 prior lines of therapy and 3 patients had 3 prior lines of therapy.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.